Next Article in Journal
Tick-Borne Flaviviruses Depress AKT Activity during Acute Infection by Modulating AKT1/2
Next Article in Special Issue
Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interaction Deep Learning Model
Previous Article in Journal
An Unconventional Flavivirus and Other RNA Viruses in the Sea Cucumber (Holothuroidea; Echinodermata) Virome
Previous Article in Special Issue
Old Drugs with New Tricks: Efficacy of Fluoroquinolones to Suppress Replication of Flaviviruses
Review

Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak

1
School of Science, Monash University, Bandar Sunway, Subang Jaya 47500, Selangor Darul Ehsan, Malaysia
2
Tropical Medicine & Biology Platform, Monash University, Subang Jaya 47500, Selangor Darul Ehsan, Malaysia
*
Author to whom correspondence should be addressed.
Received: 3 July 2020 / Revised: 2 August 2020 / Accepted: 21 August 2020 / Published: 22 September 2020
(This article belongs to the Special Issue Drug-Repositioning Opportunities for Antiviral Therapy)
Traditionally, drug discovery utilises a de novo design approach, which requires high cost and many years of drug development before it reaches the market. Novel drug development does not always account for orphan diseases, which have low demand and hence low-profit margins for drug developers. Recently, drug repositioning has gained recognition as an alternative approach that explores new avenues for pre-existing commercially approved or rejected drugs to treat diseases aside from the intended ones. Drug repositioning results in lower overall developmental expenses and risk assessments, as the efficacy and safety of the original drug have already been well accessed and approved by regulatory authorities. The greatest advantage of drug repositioning is that it breathes new life into the novel, rare, orphan, and resistant diseases, such as Cushing’s syndrome, HIV infection, and pandemic outbreaks such as COVID-19. Repositioning existing drugs such as Hydroxychloroquine, Remdesivir, Ivermectin and Baricitinib shows good potential for COVID-19 treatment. This can crucially aid in resolving outbreaks in urgent times of need. This review discusses the past success in drug repositioning, the current technological advancement in the field, drug repositioning for personalised medicine and the ongoing research on newly emerging drugs under consideration for the COVID-19 treatment. View Full-Text
Keywords: drug repositioning; novel diseases; orphan diseases; drug personalisation; COVID-19; HIV; Cushing’s syndrome drug repositioning; novel diseases; orphan diseases; drug personalisation; COVID-19; HIV; Cushing’s syndrome
Show Figures

Figure 1

MDPI and ACS Style

Low, Z.Y.; Farouk, I.A.; Lal, S.K. Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak. Viruses 2020, 12, 1058. https://0-doi-org.brum.beds.ac.uk/10.3390/v12091058

AMA Style

Low ZY, Farouk IA, Lal SK. Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak. Viruses. 2020; 12(9):1058. https://0-doi-org.brum.beds.ac.uk/10.3390/v12091058

Chicago/Turabian Style

Low, Zheng Y., Isra A. Farouk, and Sunil K. Lal 2020. "Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak" Viruses 12, no. 9: 1058. https://0-doi-org.brum.beds.ac.uk/10.3390/v12091058

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop